Included in the Standard of Practice Guidelines for the screening and surveillance of Barrett’s esophagus, WATS3D is our proprietary diagnostic platform for reliably identifying precancerous cells in the esophagus.
NEW! Learn why WATS3D is the right choice for you and your patients.
Technology
Changing the landscape of cancer prevention through innovative technology solutions.
WATS3D provides physicians with a more effective endoscopic method of sampling tissue from the esophagus. It allows:
Limitations of the Seattle protocol:
"An estimated 33% of esophageal adenocarcinomas were diagnosed within 1 year of negative index endoscopy.”
— David A. Johnson, MD reviewing Visrodia K et al. Gastroenterology 2016 Mar
fig. WATS3D instrument sampling a short-segment Barrett's.
Finding a Needle in a Haystack
A powerful AI “deep-learning”, neural network screens, identifies and ranks atypical epithelium to reliably detect precancer (dysplasia) more readily.
Unique information-rich, view of tissue
Advanced 3D imaging technology virtually slices and then synthesizes all of the layers of tissue, into a single 3D image for the pathologists to analyze.
This allows for a more definitive diagnosis of dysplasia in cases that would otherwise be reported as negative or indefinite for dysplasia.
Confirmation of the diagnosis
Immunohistochemistry is used to help identify Barrett's esophagus and dysplasia where applicable.
With WATS3D, areas identified by the neural network as the most likely to be dysplastic, pathologists are able to quickly identify and grade dysplasia in higher percentage of positive cases and with far greater diagnostic accuracy.
Traditional esophageal histopathology on forceps biopsy specimens are well-known to suffer from high interobserver variability and high miss rates of dysplasia and cancer.
WATS3D pathologists gathers information from both the 3D images as well as the cytology specimens using histocytology techniques to make more accurate diagnoses, and genetic testing allows pathologists to consistently make a diagnosis based on the most advanced science available.
Prashanth R. Vennalaganti, MD , Vijay Naag Kanakadandi, MD, Seth A. Gross,MD, Sravanthi Parasa, MD, MPH, Kenneth K. Wang, MD, Neil Gupta , MD, MPH and Prateek Sharma.
Am J Gastroenterol, 28 April 2015; doi: 10.1038/ajg.2015.116
WATS3D provides physicians with a more effective endoscopic method of sampling tissue from the esophagus. It allows:
Limitations of the Seattle protocol:
"An estimated 33% of esophageal adenocarcinomas were diagnosed within 1 year of negative index endoscopy.”
— David A. Johnson, MD reviewing Visrodia K et al. Gastroenterology 2016 Mar
fig. WATS3D instrument sampling a short-segment Barrett's.
Finding a Needle in a Haystack
A powerful AI “deep-learning”, neural network screens, identifies and ranks atypical epithelium to reliably detect precancer (dysplasia) more readily.
Unique information-rich, view of tissue
Advanced 3D imaging technology virtually slices and then synthesizes all of the layers of tissue, into a single 3D image for the pathologists to analyze.
This allows for a more definitive diagnosis of dysplasia in cases that would otherwise be reported as negative or indefinite for dysplasia.
Confirmation of the diagnosis
Immunohistochemistry is used to help identify Barrett's esophagus and dysplasia where applicable.
With WATS3D, areas identified by the neural network as the most likely to be dysplastic, pathologists are able to quickly identify and grade dysplasia in higher percentage of positive cases and with far greater diagnostic accuracy.
Traditional esophageal histopathology on forceps biopsy specimens are well-known to suffer from high interobserver variability and high miss rates of dysplasia and cancer.
WATS3D pathologists gathers information from both the 3D images as well as the cytology specimens using histocytology techniques to make more accurate diagnoses, and genetic testing allows pathologists to consistently make a diagnosis based on the most advanced science available.
Prashanth R. Vennalaganti, MD , Vijay Naag Kanakadandi, MD, Seth A. Gross,MD, Sravanthi Parasa, MD, MPH, Kenneth K. Wang, MD, Neil Gupta , MD, MPH and Prateek Sharma.
Am J Gastroenterol, 28 April 2015; doi: 10.1038/ajg.2015.116
Clinical Data
Adjunct use of our diagnostic platform has been vigorously tested for effectiveness in a clinical setting. Our largest study to date, involving more than 12,000 patients, yielded the results above. To put it simply: WATS3D has demonstrated reliable, consistent detection of more disease than standard biopsy methods alone.
Case Studies
68 year-old female with a chronic history of achalasia that had been treated with pneumatic dilation. Patient had been well managed for decades but developed persistent reflux symptoms. Forceps biopsy results were positive for Barrett’s metaplasia without dysplasia. WATS3D results demonstrated columnar epithelium with goblet cell metaplasia (Barrett's esophagus) with low-grade dysplasia involving the crypt.
"We need to make sure we use a procedure that’s accurate, safe, efficient, and cost effective: For my practice, WATS3D checks all the boxes.”
Matthew McKinley, MD
Chairman, Department of Digestive Services, ProHEALTH Care Associates, New York
Education & Training
Ready to make your next EGD far more reliable? See how easy it is to implement WATS3D, the standard of care for the screening and surveillance of Barrett's esophagus, into your practice?
